BNTX in “China Becomes Pharma's Global R&D Engine”
BioNTech SE
BioNTech has built a broad portfolio of China-sourced ADC and immuno-oncology programs through deals with companies including Duality Biologics and MediLink Therapeutics.
BNTX impact map — “China Becomes Pharma's Global R&D Engine”
How this story travels from the headline to BNTX’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading BNTX impact map…
Price history, marked with story events
Sep 28, 2022 – Sep 29, 2023 · 253 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
China Becomes Pharma's Global R&D Engine
Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
BULL side — BioNTech has built a broad portfolio of China-sourced ADC and immuno-oncology programs through deals with companies including Duality Biologics and MediLink Therapeutics.
Read the full China Becomes Pharma's Global R&D Engine story